Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The polypill and cardiovascular disease.

Authors: James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal: JAMA Date: 2004-02-04 Impact factor: 56.272

7. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study.

Authors: Jeppe Frederiksen; Klaus Juul; Peer Grande; Gorm B Jensen; Torben V Schroeder; Anne Tybjaerg-Hansen; Børge G Nordestgaard
Journal: Blood Date: 2004-06-29 Impact factor: 22.113

8. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.

Authors: Charles H Hennekens; Frank M Sacks; Andrew Tonkin; J Wouter Jukema; Robert P Byington; Bertram Pitt; Donald A Berry; Scott M Berry; Neville F Ford; Andrew J Walker; Kannan Natarajan; Chen Sheng-Lin; Frederick T Fiedorek; Rene Belder
Journal: Arch Intern Med Date: 2004-01-12

9. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.

Authors: Alan A Montgomery; Tom Fahey; Yoav Ben-Shlomo; James Harding
Journal: J Hypertens Date: 2003-09 Impact factor: 4.844

The polypill and cardiovascular disease.

1. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?

2. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

3. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis.

4. An update on aspirin in the primary prevention of cardiovascular disease.

5. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.

6. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

7. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study.

8. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.

9. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.

10. A strategy to reduce cardiovascular disease by more than 80%.

1. How have you used your SOAP today?: Considering the effects of food and environment on gene expression.

2. Prescribing statins.

Review 3. Issues to consider in the pharmaceutical development of a cardiovascular polypill.

Review 4. Novel treatments for cardiovascular disease prevention.

5. What clinical pharmacology means to us.

6. One pill, four questions: what we still need to know about reducing cardiovascular risk with combination therapy.